ASP 2408

Drug Profile

ASP 2408

Alternative Names: ASP-2408

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Maxygen
  • Developer Astellas Pharma
  • Class Antirheumatics; Immunoglobulin fusion proteins
  • Mechanism of Action CD28 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 01 Nov 2013 Discontinued - Phase-I for Rheumatoid arthritis in Japan (SC)
  • 01 Nov 2013 Discontinued - Phase-I for Rheumatoid arthritis in USA (IV)
  • 01 Oct 2013 Astellas Pharma completes a phase I trial in Healthy volunteers in Japan (NCT02140125)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top